Meta-analysis on effect of compound Danshen injection in treating neonatal hypoxic-ischemic encephalopathy.
- Author:
Xiong-Feng HUANG
;
Jian-Min WANG
;
Qiao CHEN
;
Yan-Yan WEI
;
Hong-Wei CHEN
- Publication Type:Journal Article
- MeSH:
Drugs, Chinese Herbal;
administration & dosage;
Humans;
Hypoxia-Ischemia, Brain;
drug therapy;
Infant, Newborn;
Infant, Newborn, Diseases;
drug therapy;
Injections;
Randomized Controlled Trials as Topic
- From:
China Journal of Chinese Materia Medica
2015;40(1):141-148
- CountryChina
- Language:Chinese
-
Abstract:
To systematically evaluate the clinical efficacy and safety of compound Danshen injection in treating hypoxic-ischemic encephalopathy (HIE) of newborns. Computer retrievals were made in PubMed, Embase, Cochrane Library, CBM, CNKI, VIP and China info (before May 2014) and relevant literature references, and manual retrievals were made for journals and conference papers, in order to collect randomized or semi-randomized controlled trials concerning compound Danshen injection in the treatment of neonatal HIE. The quality of included references was evaluated according to literatures recommended by Cochrane Handbook. RevMan 5. 3 software was applied in the statistical treatment. Finally, a total of 13 randomized controlled trials were included, covering 1,211 patients (including 639 patients in the compound Danshen injection-treated group and 572 patients in the control group). Meta-analysis results showed that the routine treatment combined with compound Danshen injection can improve the treatment efficiency of neonatal HIE [RR = 1.28; 95% CI (1.21-1.36)], reduce the mortality rate [RR = 0.42; 95% CI (0.23-0.75)] and the incidence of long-term neurological sequelae [RR = 0.48; 95% CI (0.35-0.65)], with statistical differences. No fatal side effect was observed in all of included trials. So far, limited evidences in this study proved that the application of compound Danshen injection in the treatment of neonatal HIE can enhance the clinical efficiency. However, because of the low quality of the included trials, more well-designed and large-scale multi-center randomized controlled trials shall be made in the future.
